461 related articles for article (PubMed ID: 38384463)
1. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
[TBL] [Abstract][Full Text] [Related]
2. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
3. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
4. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
6. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
Hartupee C; Nagalo BM; Chabu CY; Tesfay MZ; Coleman-Barnett J; West JT; Moaven O
Front Immunol; 2024; 15():1287459. PubMed ID: 38361931
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
Sperb N; Tsesmelis M; Wirth T
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
[TBL] [Abstract][Full Text] [Related]
10. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers.
Taherian M; Wang H; Wang H
Cells; 2022 Sep; 11(19):. PubMed ID: 36231030
[TBL] [Abstract][Full Text] [Related]
15. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
Muller M; Haghnejad V; Schaefer M; Gauchotte G; Caron B; Peyrin-Biroulet L; Bronowicki JP; Neuzillet C; Lopez A
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205742
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
19. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
20. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
